Goldman Sachs Starts Precision BioSciences Inc. (DTIL) at Buy

Goldman Sachs analyst Salveen Richter initiates coverage on Precision BioSciences Inc. (NASDAQ: DTIL) with a Buy rating and a price target of $24.00.

• Will be looking for an IND filing for PBCAR20A in R/R CLL and CD19-NHL to generate some upside.
• Will also watch for selection of a second lead in vivo gene correction program behind GILD-partnered hepatitis B virus.
• Has positive view on potential proof of concept in greenhouse studies for canola oil program.

For an analyst ratings summary and ratings history on Precision BioSciences Inc. click here. For more ratings news on Precision BioSciences Inc. click here.

Shares of Precision BioSciences Inc. closed at $12.18 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald